Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 13/20 | 0.53 |
| ▸ | TEK | Q02763 | 9/20 | 0.53 |
| ▸ | LCK | P06239 | 8/20 | 0.53 |
| ▸ | SRC | P12931 | 3/20 | 0.53 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.51 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.51 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.51 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.51 |
| ▸ | PRKDC | P78527 | 1/20 | 0.51 |
| ▸ | RET | P07949 | 8/20 | 0.51 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.50 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.50 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.50 |
| ▸ | PI4KA | P42356 | 1/20 | 0.50 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.50 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.50 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.50 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25141970 | 0.81 | PIK3CD (0.37) | KDRTEKLCKSRCPIK3CD | |
| SCHEMBL30582556 | 0.81 | ADORA2A (0.43) | KDRTEKLCKSRCPIK3CD | |
| SCHEMBL6925128 | 0.81 | ADORA2A (0.43) | KDRTEKLCKSRCPIK3CD | |
| SCHEMBL2618932 | 0.81 | PIK3CD (0.52) | KDRTEKLCKSRCPIK3CD | |
| SCHEMBL22327439 | 0.81 | KDR (0.51) | KDRTEKLCKSRCPIK3CD | |
| SCHEMBL870102 | 0.80 | PIK3CD (0.51) | KDRTEKLCKSRCPIK3CD | |
| SCHEMBL6363939 | 0.80 | KDR (0.53) | KDRTEKLCKSRCPIK3CD | |
| SCHEMBL24258000 | 0.80 | PIK3CD (0.51) | KDRTEKLCKSRCPIK3CD | |
| SCHEMBL1783992 | 0.80 | PIK3CD (0.51) | KDRTEKLCKSRCPIK3CD | |
| SCHEMBL6364419 | 0.80 | PIK3CD (0.51) | KDRTEKLCKSRCPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12031179-B2 | Methods and compositions for reducing nucleotide impurities | Singular Genomics Systems, Inc. (US) | 2024-07-09 | — | — | US | disclosed |
| EP-4081653-B1 | METHODS FOR LONG READ SEQUENCING | SINGULAR GENOMICS SYSTEMS INC (US) | 2024-07-03 | — | — | EP | disclosed |
| US-11913071-B2 | Methods and compositions for sequencing complementary polynucleotides | Singular Genomics Systems, Inc. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230340592-A1 | TARGETED SEQUENCING | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-10-26 | — | — | US | disclosed |
| US-11788133-B2 | Methods and compositions for sequencing complementary polynucleotides | Singular Genomics Systems, Inc. (US) | 2023-10-17 | — | — | US | disclosed |
| US-11788133-B2 | Methods and compositions for sequencing complementary polynucleotides | Singular Genomics Systems, Inc. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230295437-A1 | SILICON CONTAINING DETECTABLE COMPOUNDS | Singular Genomics Systems, Inc. | 2023-09-21 | — | — | US | disclosed |
| US-20230295437-A1 | SILICON CONTAINING DETECTABLE COMPOUNDS | Singular Genomics Systems, Inc. | 2023-09-21 | — | — | US | disclosed |
| US-20230265505-A1 | METHODS AND COMPOSITIONS FOR REDUCING NUCLEOTIDE IMPURITIES | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-08-24 | — | — | US | disclosed |
| US-20230265505-A1 | METHODS AND COMPOSITIONS FOR REDUCING NUCLEOTIDE IMPURITIES | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-08-24 | — | — | US | disclosed |
| US-7960396-B2 | Inhibitors of Bruton's tyrosine kinase | PHARMACYCLICS, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-20110008257-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| US-20100331350-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100331350-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100324050-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. A DELAWARE CORPORATION (US) | 2010-12-23 | — | — | US | disclosed |
| US-7825118-B2 | 4-Amino-3-phenyl-1H-pyrazolo[3,4-d]pyrimidine derivatives; can be covalently bonded to Bruton's tyrosine kinase; autoimmune diseases, lymphoma, leukemia; antiproliferative, anticarcinogenic and antiinflammatory agents | PHARMACYCLICS, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| US-20100254905-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC | 2010-10-07 | — | — | US | disclosed |
| US-7732454-B2 | 4-Amino-3-phenyl-1H-pyrazolo[3,4-d]pyrimidine derivatives; can be covalently bonded to Bruton's tyrosine kinase; autoimmune diseases, lymphoma, leukemia; antiproliferative, anticarcingogenic and antiinflammatory agents | PHARMACYCLICS, INC. (US) | 2010-06-08 | — | — | US | disclosed |
| US-20080139582-A1 | 4-Amino-3-phenyl-1H-pyrazolo[3,4-d]pyrimidine derivatives; can be covalently bonded to Bruton's tyrosine kinase; autoimmune diseases, lymphoma, leukemia; antiproliferative, anticarcinogenic and antiinflammatory agents | PHARMACYCLICS, INC. (US) | 2008-06-12 | — | — | US | disclosed |
| US-20080076921-A1 | 4-Amino-3-phenyl-1H-pyrazolo[3,4-d]pyrimidine derivatives; can be covalently bonded to Bruton's tyrosine kinase; autoimmune diseases, lymphoma, leukemia; antiproliferative, anticarcingogenic and antiinflammatory agents | PHARMACYCLICS, INC. (US) | 2008-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295437-A1 | SILICON CONTAINING DETECTABLE COMPOUNDS | AS3MT, SCLY, NASP | KDR 4624/4885TEK 4825/4885LCK 1511/4885 |
| US-20100324050-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LCK, LYN | KDR 2089/4885TEK 3185/4885LCK 2/4885 |
| US-20100331350-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LCK, LYN | KDR 2089/4885TEK 3185/4885LCK 2/4885 |
| US-20100254905-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, ABL2 | KDR 1295/4885TEK 1902/4885LCK 23/4885 |
| US-20110008257-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LCK, LYN | KDR 2089/4885TEK 3185/4885LCK 2/4885 |
| US-20080139582-A1 | 4-Amino-3-phenyl-1H-pyrazolo[3,4-d]pyrimidine derivatives; can be covalently bonded to Bruton's tyrosine kinase; autoimmune diseases, lymphoma, leukemia; antiproliferative, anticarcinogenic and antiinflammatory agents | BTK, LCK, LYN | KDR 2006/4885TEK 2377/4885LCK 2/4885 |
| US-20080076921-A1 | 4-Amino-3-phenyl-1H-pyrazolo[3,4-d]pyrimidine derivatives; can be covalently bonded to Bruton's tyrosine kinase; autoimmune diseases, lymphoma, leukemia; antiproliferative, anticarcingogenic and antiinflammatory agents | BTK, LCK, LYN | KDR 2105/4885TEK 2394/4885LCK 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.